Moreover, we unveiled a previously unknown Abl kinase-dependent retrograde signaling pathway mediated by transmembrane Sema6C, upregulating FAK, ERK and YAP activity in cancer cells, and conferring refractoriness to cell cycle inhibitory mechanisms. The gene discussed is SEMA6C; the disease is cancer.